Rosas, Ivan O. http://orcid.org/0000-0003-4622-618X
Diaz, George
Gottlieb, Robert L.
Lobo, Suzana M.
Robinson, Philip
Hunter, Bradley D.
Cavalcante, Adilson W.
Overcash, J. Scott
Hanania, Nicola A.
Skarbnik, Alan
Garcia-Diaz, Julia
Gordeev, Ivan
Carratalà, Jordi
Gordon, Oliver
Graham, Emily
Lewin-Koh, Nicholas
Tsai, Larry
Tuckwell, Katie
Cao, Huyen
Brainard, Diana
Olsson, Julie K.
Funding for this research was provided by:
f. hoffmann-la roche ltd.
Article History
Received: 13 July 2021
Accepted: 7 August 2021
First Online: 5 October 2021
Declarations
:
: IOR Grant from Roche/Genentech related to the submitted work and grant from Genentech and personal fees from Genentech, Boehringer, and Bristol Myers Squibb outside the submitted work. GD: Grants from Gilead Sciences, Regeneron Inc., Roche, Boehringer Ingelheim, and Edasa Biotech outside the submitted work. Gilead Medical Affairs sentinel panel and Scientific Advisory Board for Safeology Inc. RLG: Personal fees from Eli Lilly, Gilead Sciences Inc., GlaxoSmithKline, Johnson and Johnson, and Roivant Sciences Inc. and nonfinancial support from Gilead Sciences Inc. outside the submitted work. SML: Investigator fees from Roche/Genentech during the conduct of the trial. PR: Nothing to disclose. BDH: Personal fees from Kite Pharma and Novartis outside the submitted work. AWC: Nothing to disclose. JSO: Institutional funding from Roche during conduct of the trial. NAH: Grants from GlaxoSmithKline, Sanofi, AstraZeneca, Genentech, Boehringer Ingelheim, Novartis, and Gossamer Bio; personal fees from GlaxoSmithKline, Sanofi, AstraZeneca, Genentech, Novartis, Regeneron, Teva, and Amgen outside the submitted work. AS: Personal fees from Genentech, AbbVie, Pharmacyclics, Janssen, Kite Pharma, Celgene, Verastem, BeiGene, Novartis, TG Therapeutics, Seattle Genetics, Morphosys, Jazz Pharmaceuticals, and Gilead Sciences and nonfinancial support from Bristol Myers Squibb outside the submitted work. JG-D: Nothing to disclose. IG: Nothing to disclose. JC: Grant provided to institution from Roche/Genentech during conduct of the trial. Grants and personal fees from Gilead Sciences Inc. outside the submitted work. OG: Employee of Roche and shareholder of Roche Holding AG. EG: Employee of Roche. NL-K: Employee of Roche/Genentech. LT: Employee of Roche/Genentech and has an unpublished patent pending, “Tocilizumab and Remdesivir Combination Therapy for COVID-19 Pneumonia.” KT: Former employee of Roche/Genentech and owns stock in Roche/Genentech. HC: Employee of Gilead Sciences Inc. DB: Former employee of and holds stock in Gilead Sciences Inc. JKO: Employee of Roche/Genentech.
: F. Hoffmann-La Roche Ltd was involved in designing the trial, performing the analyses, and writing the report. A contract research organization paid by the sponsor monitored the trial under direction and supervision of the sponsor.
: Qualified researchers may request access to individual patient level data upon publication through the clinical trial data request platform (ExternalRef removed). Further details on Roche's criteria for eligible studies are available here (ExternalRef removed). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical trial documents, see here (ExternalRef removed).